Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Searching for the Achilles’ heel of cancer

Searching for the Achilles’ heel of cancer editorial memo (2016) 9:153–154 DOI 10.1007/s12254-016-0303-3 Myeloproliferative neoplasms in the era of precision medicine Klaus Geissler Received: 21 November 2016 / Accepted: 22 November 2016 / Published online: 30 November 2016 © Springer-Verlag Wien 2016 Targeted treatment of cancer has been a vision phlebotomies and disease-related symptoms can be for hemato-oncologists for many years. Among greatly reduced with this drug. the myeloproliferative neoplasms (MPNs) chronic In contrast to the other MPNs treatment options myeloid leukemia (CML) was the first disease in in the myeloproliferative-chronic myelomonocytic which this dream has come true and in the other leukemia (MP-CMML) are still unsatisfactory. The ar- MPN entities we try to mimic this success. ticle by Sonja Burgstaller [3] clearly indicates that this CML was the first malignancy in which imatinib, disease deserves more attention, since some patients a tyrosine kinase inhibitor (TKI) which inhibits the have an extremely poor prognosis and trials inves- pathophysiologically crucial BCR-ABL protein, was tigating new agents are still limited. For the design able to profoundly inhibit the growth of the ma- of such trials agents could be selected on the basis lignant clone and to greatly improve the prognosis of new insights into the molecular pathophysiology of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Searching for the Achilles’ heel of cancer

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/searching-for-the-achilles-heel-of-cancer-FqmrbNRRJk
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0303-3
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2016) 9:153–154 DOI 10.1007/s12254-016-0303-3 Myeloproliferative neoplasms in the era of precision medicine Klaus Geissler Received: 21 November 2016 / Accepted: 22 November 2016 / Published online: 30 November 2016 © Springer-Verlag Wien 2016 Targeted treatment of cancer has been a vision phlebotomies and disease-related symptoms can be for hemato-oncologists for many years. Among greatly reduced with this drug. the myeloproliferative neoplasms (MPNs) chronic In contrast to the other MPNs treatment options myeloid leukemia (CML) was the first disease in in the myeloproliferative-chronic myelomonocytic which this dream has come true and in the other leukemia (MP-CMML) are still unsatisfactory. The ar- MPN entities we try to mimic this success. ticle by Sonja Burgstaller [3] clearly indicates that this CML was the first malignancy in which imatinib, disease deserves more attention, since some patients a tyrosine kinase inhibitor (TKI) which inhibits the have an extremely poor prognosis and trials inves- pathophysiologically crucial BCR-ABL protein, was tigating new agents are still limited. For the design able to profoundly inhibit the growth of the ma- of such trials agents could be selected on the basis lignant clone and to greatly improve the prognosis of new insights into the molecular pathophysiology of

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 30, 2016

References

  • Molecular pathogenesis of chronic myeloid leukemia
    Webersinke, G
  • Treatment of chronic myeloid leukemia
    Schmidt, S
  • Treatment of chronic myelomonocytic leukemia
    Burgstaller, S
  • Molecular pathogenesis of chronic myelomonocytic leukemia
    Geissler, K